

ForPatients

by Roche

[Early Breast Cancer](#) [Breast Cancer](#) [Er-Positive Breast Cancer](#) [HER-2 Negative Breast Cancer](#)

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (IidERA Breast Cancer)

Trial Status
Recruiting

Trial Runs In
54 Countries

Trial Identifier
NCT04961996
2021-000129-28,2023-507172-44-00
GO42784

The source of the below information is the publicly available website [ClinicalTrials.gov](#). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04961996 2021-000129-28,2023-507172-44-00 GO42784
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No